Table 2.
Number of treatment comparisons by subgroup and efficacy outcomes.
| Outcome |
||||
|---|---|---|---|---|
| Treatment comparisons n (%) | DFS n (%) | OS n (%) | pCR n (%) | |
| Overall | 21 | 13 (62%) | 12 (57%) | 16 (76%) |
| Treatment setting | ||||
| Neoadjuvant | 16 (76%) | 8 (38%) | 8 (38%) | 16 (76%) |
| Adjuvant | 4 (19%) | 4 (19%) | 4 (19%) | 0 |
| Both | 1 (5%) | 1 (5%) | 0 | 1 (5%) |
| Subgroups | ||||
| BRCA mutation subgroup reported | 6 (29%) | 4 (19%) | 0 | 6 (29%) |
| HRD status subgroup reported | 1 (5%) | 1 (5%) | 0 | 1 (5%) |
| Lymph node positive reported | 3 (14%) | 3 (14%) | 0 | 3 (14%) |
| Type of platinum agent | ||||
| Carboplatin | 18 (%) | 12 (57%) | 12 (57%) | 13 (62%) |
| Cisplatin | 2 (10%) | 0 | 0 | 2 (10%) |
| Lobaplatin | 1 (5%) | 1 (5%) | 0 | 1 (5%) |
| Type of regimen | ||||
| Different backbone | 14 (67%) | 7 (33%) | 7 (33%) | 9 (%) |
| Same backbone | 7 (33%) | 6 (29%) | 5 (24%) | 7 (%) |
| Anthracycline content in intervention arm | ||||
| Anthracycline present | 12 (57%) | 7 (33%) | 6 (29%) | 10 (47%) |
| Anthracycline free | 9 (43%) | 6 (29%) | 6 (29%) | 6 (29%) |
| Schedule of platinum agent | ||||
| 3-weekly | 14 (67%) | 9 (43%) | 8 (38%) | 11 (57%) |
| 2-weekly | 1 (5%) | 1 (5%) | 1 (5%) | 0 |
| Weekly | 5 (24%) | 3 (14%) | 3 (%) | 5 (24%) |
| Hormone receptor IHC cut-off | ||||
| >1% or not reported | 11 (57%) | 5 (24%) | 4 (19%) | 9 (43%) |
| <1% | 10 (47%) | 8 (38%) | 8 (38%) | 7 (33%) |
DFS: disease-free survival; HRD: homologous recombination deficiency; IHC: immunohistochemistry; n: number; OS: overall survival; pCR: pathological complete response.